# CEL SCI CORP

CEL SCI CORP is an other based in null, null.

## Overview

- **Organization type:** other
- **Headquarters:** null, null
- **Region:** North America
- **Address:** null
- **Assets under management:** Undisclosed

## Regulatory record

- **Reports private funds:** No

## About

CEL SCI CORP was founded to advance the development of Multikine, a leukocyte interleukin injection intended as a first-line treatment for locally advanced squamous cell carcinoma of the head and neck. The firm has no publicly disclosed founding date, named principals, or headquarters location beyond a probable US corporate address. The company has never generated revenue from product sales. Its primary capital allocation has been directed toward clinical trials, regulatory filings, and manufacturing process development for Multikine. The firm does not report a strategic asset allocation across traditional asset classes such as equities, fixed income, or real estate, nor does it disclose any portfolio companies or third-party fund commitments. CEL SCI CORP operates as a microcap public entity (OTC ticker symbol: CELS) with a market capitalization typically under $50 million. There is no evidence of a team with investment professionals, multiple offices, or adjacent vehicles such as a philanthropic foundation or operating businesses. The firm has not reported any recent operational events beyond routine regulatory filings with the SEC. The structural differentiator is the firm's identity as a single-product biotechnology company rather than a capital allocator. Unlike a conventional family office or asset manager, CEL SCI CORP does not manage third-party capital, deploy funds across a portfolio, or generate income from investments. Its sole purpose is to bring a single drug candidate through clinical development to potential commercialization.

## Sectors

- Biotechnology
- Pharmaceuticals
- Immuno-Oncology

## Questions

### What is the status of Multikine, CEL SCI CORP's lead drug candidate?

Multikine completed a global Phase 3 clinical trial (the Pivotal Trial) in patients with advanced squamous cell carcinoma of the head and neck, but as of public record, it has not received marketing approval from the FDA or any other regulatory body. The company has submitted the trial results to the FDA and continues to seek a path to approval.

### Has CEL SCI CORP ever generated revenue from product sales?

According to public filings, CEL SCI CORP has not recorded any revenue from product sales. The company has funded operations through equity offerings and debt financing, with the bulk of expenditure directed toward clinical and regulatory activities for Multikine.

### Does the company have any other drug candidates or pipeline programs?

Public disclosures indicate that CEL SCI CORP has concentrated all resources on Multikine. There is no publicly reported pipeline of additional drug candidates or research programs beyond this single asset.

### How does CEL SCI CORP's governance structure differ from a typical investment firm?

The company is governed by a board of directors and officers typical of a public corporation, not by investment professionals or family office principals. The CEO and executive leadership have backgrounds in clinical development and regulatory affairs rather than in capital management or asset allocation.

## Related profiles

- [Allarity Therapeutics](https://altss.com/profile/allarity-therapeutics-inc)
- [United Maritime Corp](https://altss.com/profile/united-maritime-corp)

---

Last updated: 2026-08-10T19:36:47.593Z

Canonical page: https://altss.com/profile/cel-sci-corp

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology